In contrast, treatment of tumor‐bearing mice with recombinant IL‐33 and ICI in vivo led to induction of eosinophils and subsequent activation of CD8+ T cells and resulted in improved tumor control and survival prolongation. This evidence concerns the gene CD8A and neoplasm.